Baicalin alleviates TNBS‑induced colitis by inhibiting PI3K/AKT pathway activation

Zhu,Lei; Shen,Hong; Gu,Pei‑Qing; Liu,Ya‑Jun; Zhang,Lu; Cheng,Jia‑Fei

doi:10.3892/etm.2020.8718

Baicalin alleviates TNBS‑induced colitis by inhibiting PI3K/AKT pathway activation

Authors:
- Lei Zhu
- Hong Shen
- Pei‑Qing Gu
- Ya‑Jun Liu
- Lu Zhang
- Jia‑Fei Cheng
View Affiliations

Affiliations: Department of Gastroenterology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 201129, P.R. China
Published online on: May 6, 2020 https://doi.org/10.3892/etm.2020.8718
Pages: 581-590

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammatory bowel diseases (IBDs) are chronic immunological disorders of the intestinal tract characterized by persistent inflammation. Baicalin, a type of flavonoid, has exhibited a wide range of pharmacological activities, including immunomodulation and anti‑inflammation. However, little is known about the therapeutic role of baicalin in IBD. The aim of the present study was to ascertain whether baicalin could be a therapeutic drug of IBD and investigate its specific mechanisms. In the present study, the results revealed that baicalin not only significantly alleviated TNBS‑induced colitis by reducing the release of IL‑6, TNF‑α and IL‑1β and increasing the level of IL‑10, but promoted the expression of tight‑junction proteins ZO‑1 and β‑catenin, which may have been achieved by blockage of the PI3K/AKT signaling pathway. In vitro, the results demonstrated that baicalin clearly inhibited the release of TNF‑α, IL‑6 and IL‑1β and promoted the expression of IL‑10 in LPS‑induced HT‑29 cells, and significantly decreased LPS‑induced HT‑29 cell apoptosis by blockage of the PI3K/AKT signaling pathway. In conclusion, the present research revealed for the first time that baicalin acted as a therapeutic drug in IBD by suppression of the PI3K/AKT signaling pathway.

View Figures

View References

1	Bitton A, Vutcovici M, Patenaude V, Sewitch M, Suissa S and Brassard P: Epidemiology of inflammatory bowel disease in Quebec: Recent trends. Inflamm Bowel Dis. 20:1770–1776. 2014.PubMed/NCBI View Article : Google Scholar
2	Bashashati M, Rezaei N, Andrews CN, Chen CQ, Daryani NE, Sharkey KA and Storr MA: Cytokines and irritable bowel syndrome: Where do we stand? Cytokine. 57:201–209. 2012.PubMed/NCBI View Article : Google Scholar
3	Cosnes J, Gower-Rousseau C, Seksik P and Cortot A: Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 140:1785–1794. 2011.PubMed/NCBI View Article : Google Scholar
4	Ananthakrishnan AN: Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 12:205–217. 2015.PubMed/NCBI View Article : Google Scholar
5	Beaugerie L and Itzkowitz SH: Cancers complicating inflammatory bowel disease. N Engl J Med. 372:1441–1452. 2015.PubMed/NCBI View Article : Google Scholar
6	Fichtner-Feigl S, Strober W, Geissler EK and Schlitt HJ: Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis. Mucosal Immunol. 1 (Suppl 1):S24–S27. 2008.PubMed/NCBI View Article : Google Scholar
7	Rungoe C, Nyboe Andersen N and Jess T: Inflammatory bowel disease and risk of coronary heart disease. Trends Cardiovasc Med. 25:699–704. 2015.PubMed/NCBI View Article : Google Scholar
8	Nyuyki KD and Pittman QJ: Toward a better understanding of the central consequences of intestinal inflammation. Ann NY Acad Sci. 1351:149–154. 2015.PubMed/NCBI View Article : Google Scholar
9	Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE and Colombel JF: Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 148:37–51 e1. 2015.PubMed/NCBI View Article : Google Scholar
10	Fonseca-Camarillo G and Yamamoto-Furusho JK: Immunoregulatory pathways involved in inflammatory bowel disease. Inflamm Bowel Dis. 21:2188–2193. 2015.PubMed/NCBI View Article : Google Scholar
11	Koelink PJ, Overbeek SA, Braber S, de Kruijf P, Folkerts G, Smit MJ and Kraneveld AD: Targeting chemokine receptors in chronic inflammatory diseases: An extensive review. Pharmacol Ther. 133:1–18. 2012.PubMed/NCBI View Article : Google Scholar
12	Mitroulis I, Alexaki VI, Kourtzelis I, Ziogas A, Hajishengallis G and Chavakis T: Leukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther. 147:123–135. 2015.PubMed/NCBI View Article : Google Scholar
13	Merga Y, Campbell BJ and Rhodes JM: Mucosal barrier, bacteria and inflammatory bowel disease: Possibilities for therapy. Dig Dis. 32:475–483. 2014.PubMed/NCBI View Article : Google Scholar
14	Chen SJ, Liu XW, Liu JP, Yang XY and Lu FG: Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier. World J Gastroenterol. 20:9468–9475. 2014.PubMed/NCBI View Article : Google Scholar
15	Zhu Y, Mahon BD, Froicu M and Cantorna MT: Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J immunol. 35:217–224. 2005.PubMed/NCBI View Article : Google Scholar
16	Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Piqué JM, Panes J, Katz JA, Gasbarrini A and Fiocchi C: TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: A novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 176:2617–2624. 2006.PubMed/NCBI View Article : Google Scholar
17	Condino G, Calabrese E, Zorzi F, Onali S, Lolli E, De Biasio F, Ascolani M, Pallone F and Biancone L: Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: A prospective study. Dig Liver Dis. 45:258–262. 2013.PubMed/NCBI View Article : Google Scholar
18	Pugliese D, Guidi L, Ferraro PM, Marzo M, Felice C, Celleno L, Landi R, Andrisani G, Pizzolante F, De Vitis I, et al: Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 42:880–888. 2015.PubMed/NCBI View Article : Google Scholar
19	Ikemoto SK, Yoshida N, Yasumoto R, Wada S, Yamamoto K and Kishimoto T: Antitumor effects of Scutellariae radix and its components baicalein, baicalin, and wogonin on bladder cancer cell lines. Urology. 55:951–955. 2000.PubMed/NCBI View Article : Google Scholar
20	Sun SJ, Wu XP, Song HL and Li GQ: Baicalin ameliorates isoproterenol-induced acute myocardial infarction through iNOS, inflammation, oxidative stress and P38MAPK pathway in rat. Int J Clin Exp Med. 8:22063–22072. 2015.PubMed/NCBI
21	Li X, Zou K, Gou J, Du Q, Li D, He X and Li Z: Effect of baicalin-copper on the induction of apoptosis in human hepatoblastoma cancer HepG2 cells. Med Oncol. 32(72)2015.PubMed/NCBI View Article : Google Scholar
22	Guo X, Chi S, Cong X, Li H, Jiang Z, Cao R and Tian W: Baicalin protects sertoli cells from heat stress-induced apoptosis via activation of the Fas/FasL pathway and Hsp72 expression. Reprod Toxicol. 57:196–203. 2015.PubMed/NCBI View Article : Google Scholar
23	Zou Y, Dai SX, Chi HG, Li T, He ZW, Wang J, Ye CG, Huang GL, Zhao B, Li WY, et al: Baicalin attenuates TNBS-induced colitis in rats by modulating the Th17/Treg paradigm. Arch Pharm Res. 38:1873–1887. 2015.PubMed/NCBI View Article : Google Scholar
24	Liu X, Gu J, Fan Y, Shi H and Jiang M: Baicalin attenuates acute myocardial infarction of rats via mediating the mitogen-activated protein kinase pathway. Biol Pharm Bull. 36:988–994. 2013.PubMed/NCBI View Article : Google Scholar
25	Lin M, Li L, Li L, Pokhrel G, Qi G, Rong R and Zhu T: The protective effect of baicalin against renal ischemia-reperfusion injury through inhibition of inflammation and apoptosis. BMC Complement Altern Med. 14(19)2014.PubMed/NCBI View Article : Google Scholar
26	Cui L, Feng L, Zhang ZH and Jia XB: The anti-inflammation effect of baicalin on experimental colitis through inhibiting TLR4/NF-κB pathway activation. Int Immunopharmacol. 23:294–303. 2014.PubMed/NCBI View Article : Google Scholar
27	Zhang Y, Li X, Ciric B, Ma CG, Gran B, Rostami A and Zhang GX: Therapeutic effect of baicalin on experimental autoimmune encephalomyelitis is mediated by SOCS3 regulatory pathway. Sci Rep. 5(17407)2015.PubMed/NCBI View Article : Google Scholar
28	Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR and Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 96:795–803. 1989.PubMed/NCBI
29	Siggers RH and Hackam DJ: The role of innate immune-stimulated epithelial apoptosis during gastrointestinal inflammatory diseases. Cell Mol Life Sci. 68:3623–3634. 2011.PubMed/NCBI View Article : Google Scholar
30	Marini M, Bamias G, Rivera-Nieves J, Moskaluk CA, Hoang SB, Ross WG, Pizarro TT and Cominelli F: TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci USA. 100:8366–8371. 2003.PubMed/NCBI View Article : Google Scholar
31	Cario E: Barrier-protective function of intestinal epithelial Toll-like receptor 2. Mucosal Immunol. 1 (Suppl 1):S62–S66. 2008.PubMed/NCBI View Article : Google Scholar
32	Kaplan GG: The global burden of IBD: From 2015 to 2025. Nat Rev Gastroenterol Hepatol. 12:720–727. 2015.PubMed/NCBI View Article : Google Scholar
33	Baumgart DC and Sandborn WJ: Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet. 369:1641–1657. 2007.PubMed/NCBI View Article : Google Scholar
34	Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S and Neurath MF: Chemically induced mouse models of intestinal inflammation. Nat Protoc. 12:1295–1309. 2017.PubMed/NCBI View Article : Google Scholar
35	Randhawa PK, Singh K, Singh N and Jaggi AS: A review on chemical-induced inflammatory bowel disease models in rodents. Korean J Physiol Pharmacol. 18:279–288. 2014.PubMed/NCBI View Article : Google Scholar
36	Wallace KL, Zheng LB, Kanazawa Y and Shih DQ: Immunopathology of inflammatory bowel disease. World J Gastroenterol. 20:6–21. 2014.PubMed/NCBI View Article : Google Scholar
37	Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, et al: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nat Med. 6:583–588. 2000.PubMed/NCBI View Article : Google Scholar
38	Atreya R and Neurath MF: Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol. 28:187–196. 2005.PubMed/NCBI View Article : Google Scholar
39	Atreya R and Neurath MF: New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol. 1:175–182. 2008.PubMed/NCBI View Article : Google Scholar
40	Qiu W, Wu B, Wang X, Buchanan ME, Regueiro MD, Hartman DJ, Schoen RE, Yu J and Zhang L: PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J Clin Invest. 121:1722–1732. 2011.PubMed/NCBI View Article : Google Scholar
41	Lin W, Ma C, Su F, Jiang Y, Lai R, Zhang T, Sun K, Fan L, Cai Z, Li Z, et al: Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice. Gut. 66:597–610. 2017.PubMed/NCBI View Article : Google Scholar
42	Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M and Schulzke JD: Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut. 53:1295–1302. 2004.PubMed/NCBI View Article : Google Scholar
43	Gu L, Ge Z, Wang Y, Shen M and Zhao P: Activating transcription factor 3 promotes intestinal epithelial cell apoptosis in Crohn's disease. Pathol Res Pract. 214:862–870. 2018.PubMed/NCBI View Article : Google Scholar
44	Rodrigues RC, Pocheron AL, Cappelier JM, Tresse O and Haddad N: An adapted in vitro assay to assess Campylobacter jejuni interaction with intestinal epithelial cells: Taking into stimulation with TNFα. J Microbiol Methods. 149:67–72. 2018.PubMed/NCBI View Article : Google Scholar
45	Gu L, Zhao J, Zhang S, Xu W, Ni R and Liu X: Runt-related transcription factor 2 (RUNX2) inhibits apoptosis of intestinal epithelial cells in Crohn's disease. Pathol Res Pract. 214:245–252. 2018.PubMed/NCBI View Article : Google Scholar
46	Li M, Zhang S, Qiu Y, He Y, Chen B, Mao R, Cui Y, Zeng Z and Chen M: Upregulation of miR-665 promotes apoptosis and colitis in inflammatory bowel disease by repressing the endoplasmic reticulum stress components XBP1 and ORMDL3. Cell Death Dis. 8(e2699)2017.PubMed/NCBI View Article : Google Scholar
47	Yan L, Wang L, Bai J, Miao X, Zeng W, Hua X, Ni R, Zhang D and Tang Q: Chromosome region maintenance-1 (CRM1) regulates apoptosis of intestinal epithelial cells via p27kip1 in Crohn's disease. Clin Res Hepatol Gastroenterol. 41:445–458. 2017.PubMed/NCBI View Article : Google Scholar
48	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006.PubMed/NCBI View Article : Google Scholar
49	Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Baròn M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004.PubMed/NCBI View Article : Google Scholar
50	Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009.PubMed/NCBI View Article : Google Scholar
51	Chen W, Liu Y, Xue G, Zhang L, Zhang L and Shao S: Diazoxide protects L6 skeletal myoblasts from H2O2-induced apoptosis via the phosphatidylinositol-3 kinase/Akt pathway. Inflamm Res. 65:53–60. 2016.PubMed/NCBI View Article : Google Scholar
52	Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, Richter J, Bojarski C, Schumann M and Fromm M: Epithelial tight junctions in intestinal inflammation. Ann NY Acad Sci. 1165:294–300. 2009.PubMed/NCBI View Article : Google Scholar
53	Johansson ME: Mucus layers in inflammatory bowel disease. Inflamm Bowel Dis. 20:2124–2131. 2014.PubMed/NCBI View Article : Google Scholar